𝔖 Bobbio Scriptorium

✦ LIBER ✦

A 13-week, double-blind, placebo-controlled, parallel, multicenter study of eprosartan mesylate given in titrated doses of 600mg or 1200 mg once daily in patients with isolated systolic hypertension

✍ Scribed by Henry A. Punzi; Connie F. Punzi

Book ID: 117602011
Publisher: Nature Publishing Group
Year: 2003
Tongue: English
Weight: 33 KB
Volume: 16
Category: Article
ISSN: 0895-7061
DOI: 10.1016/s0895-7061(03)00413-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Once-daily eprosartan mesylate in the tr

Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study

✍ Punzi, H A; Punzi, C F 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 230 KB

An 8-week, double-blind, placebo-control

An 8-week, double-blind, placebo-controled, multicenter, Ambulatory Blood Pressure Monitoring (ABPM) study of Teveten (Eprosartan Mesylate) 600mg and 1200mg QD in patients with essential hypertension

✍ Henry A. Punzi; Connie F. Punzi 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 61 KB

Evaluation of the dose—response relation

Evaluation of the dose—response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension

✍ Juan G. Puig; Heribert Schunkert; Addison A. Taylor; Sam Boye; James Jin; Debora 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Efficacy and tolerability of nebivolol m

Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: A retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension

✍ F. Wilford Germino 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 143 KB